Viscosupplementation Market Size, Share & Forecast Analysis to 2030

The global viscosupplementation market size was valued at around USD 5 billion in 2025 and projected to grow at a significant CAGR of over 6% during the forecast period from 2026 to 2030. The market is experiencing steady growth, driven by the increasing prevalence of osteoarthritis and the rising preference for minimally invasive therapies that provide effective and long-lasting joint pain relief. Growing geriatric populations, expanding access to orthopedic care, and increasing awareness of hyaluronic acid-based treatments are supporting market demand. In addition, advancements in viscosupplementation formulations, including longer-lasting and single-injection products, are improving patient convenience and clinical outcomes.

Market Snapshot:

Key Insights:

• Rising osteoarthritis prevalence is increasing demand for viscosupplementation therapies as patients seek effective non-surgical pain management solutions.
• Single-injection viscosupplementation products are gaining preference due to improved convenience, treatment adherence, and reduced healthcare visits.
• Knee osteoarthritis remains the leading application segment because of high disease burden and widespread clinical adoption.
• North America dominates the market due to advanced healthcare infrastructure, strong reimbursement access, and higher treatment adoption.

Key Factors Driving the Viscosupplementation Market Growth

The rising prevalence of osteoarthritis and the growing global aging population are key factors driving the viscosupplementation market. Increasing cases of knee osteoarthritis have accelerated the demand for minimally invasive therapies that help reduce pain, improve joint function, and delay joint replacement surgeries. According to the World Health Organization (WHO), approximately 528 million people worldwide were living with osteoarthritis in 2019, representing a 113% increase since 1990, and knee osteoarthritis accounted for 365 million cases globally, highlighting the expanding patient pool for viscosupplementation therapies.

Another major driver is the continuous advancement of hyaluronic acid formulations and the increasing adoption of single-injection, cross-linked, and longer-lasting products that enhance patient convenience and clinical outcomes. Healthcare providers are increasingly incorporating viscosupplementation into comprehensive osteoarthritis management plans to improve mobility while reducing reliance on long-term analgesics and delaying surgical interventions, particularly among elderly patients with mild-to-moderate knee osteoarthritis.

Key Growth Drivers:

• Rising prevalence of osteoarthritis and aging population increasing the demand for non-surgical treatments that effectively relieve joint pain and improve mobility.
• Growing adoption of minimally invasive hyaluronic acid injections as a preferred conservative treatment to delay joint replacement surgeries and enhance patient outcomes.
• Advancements in single-injection and long-lasting viscosupplementation formulations improving treatment convenience, clinical effectiveness, and adoption across hospitals and orthopedic clinics.

Viscosupplementation Market Restraints

The viscosupplementation market faces significant challenges due to the high cost of treatment and inconsistent reimbursement policies across different healthcare systems. In several countries, limited insurance coverage and varying clinical guideline recommendations discourage both physicians and patients from opting for hyaluronic acid injections, particularly in cost-sensitive markets. These factors can reduce treatment accessibility and slow market adoption despite growing demand for non-surgical osteoarthritis management.

Another key restraint is the ongoing debate regarding the clinical effectiveness of viscosupplementation compared with other osteoarthritis treatments. Differences in patient response, disease severity, and product formulations have led to mixed outcomes in clinical studies, resulting in cautious adoption by some healthcare providers. Additionally, the availability of alternative therapies, including corticosteroid injections, physical therapy, platelet-rich plasma (PRP), and joint replacement surgery for advanced cases, intensifies competition and limits the widespread use of viscosupplementation products.

Future Opportunities Reshaping the Viscosupplementation Market’s Evolution

The viscosupplementation market presents significant opportunities through the rising demand for advanced osteoarthritis management solutions and the growing preference for minimally invasive therapies. Healthcare providers are increasingly focusing on treatments that improve mobility, reduce pain, and delay surgical procedures, creating growth opportunities for hyaluronic acid-based products. Additionally, emerging markets are offering new opportunities due to improving healthcare infrastructure, increasing orthopedic care access, and growing awareness of alternative joint pain management options.

Another major opportunity is the development of innovative viscosupplementation products, including bioengineered hyaluronic acid formulations, combination therapies, and extended-duration injections that enhance treatment effectiveness and patient convenience. According to the Osteoarthritis Action Alliance (OAAA) at the University of North Carolina, osteoarthritis affects more than 32.5 million adults in the United States and is a leading cause of disability, with knee osteoarthritis being one of the most common forms of the disease. This growing disease burden creates significant opportunities for viscosupplementation therapies aimed at managing joint pain and improving patient mobility.

Key Growth Opportunities:

• Growing demand for non-surgical osteoarthritis treatments as patients and healthcare providers increasingly seek therapies that reduce pain, improve mobility, and delay joint replacement procedures.
• Expansion in emerging markets driven by improving healthcare infrastructure, rising orthopedic care access, and increasing awareness of advanced joint pain management solutions.
• Innovation in hyaluronic acid-based formulations including single-injection, long-acting, and next-generation viscosupplementation products that enhance patient convenience and treatment effectiveness.

Industry Trends Shaping the Global Viscosupplementation Market

The viscosupplementation market offers significant growth opportunities due to the increasing demand for effective and minimally invasive osteoarthritis management solutions. Rising healthcare expenditure, improving access to orthopedic treatments, and growing patient preference for alternatives to surgery are encouraging the adoption of hyaluronic acid-based therapies. Emerging economies are also creating new opportunities as healthcare systems expand and awareness of advanced joint care treatments increases among patients and physicians.

Another key opportunity lies in the development of innovative viscosupplementation products, including longer-lasting formulations, combination therapies, and single-injection treatments designed to improve patient compliance and clinical outcomes. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), osteoarthritis is more common among women than men, particularly after age 50, and risk increases with age due to factors such as joint wear, previous injuries, and obesity. The growing prevalence among aging populations and high-risk groups is creating opportunities for viscosupplementation companies to develop targeted therapies and expand access to advanced joint care solutions.

Market Segments Insights:

By Product Type: The Single-injection Segment Dominated the Global Viscosupplementation Market

The global viscosupplementation market is bifurcated into product type, source, application, end-usr, and geography. On the basis of product type, the single-injection segment dominated the market, driven by increasing patient preference for convenient treatment options that require fewer healthcare visits while providing sustained symptom relief. Advances in hyaluronic acid technology, including cross-linked and high molecular weight formulations, have improved the durability and effectiveness of single-dose products. These benefits make single-injection therapies particularly attractive for elderly patients and individuals seeking minimally invasive osteoarthritis management with reduced treatment burden.

Healthcare providers are increasingly adopting single-injection viscosupplementation products due to improved patient compliance, simplified treatment administration, and reduced resource utilization compared with multi-injection regimens. Recent product advancements are further strengthening this segment’s growth potential. In April 2025, the U.S. Food and Drug Administration (FDA) approved a supplemental application for HYMOVIS® ONE, developed by Fidia Farmaceutici S.p.A., expanding its indication for the treatment of pain associated with knee osteoarthritis in patients who have not responded adequately to conservative therapies. The approval supports the growing shift toward advanced single-injection hyaluronic acid therapies that improve treatment convenience and patient adherence.

By Application: The Knee Osteoarthritis Sub-category Holds the Largest Share of Global Viscosupplementation Market

On the basis of application, the global viscosupplementation market is further segmented into knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, ankle osteoarthritis, and others. The knee osteoarthritis segment dominates the market, owing to the high prevalence of knee joint degeneration and the extensive clinical use of hyaluronic acid injections for pain management and mobility improvement. The knee is one of the most commonly affected joints due to continuous weight-bearing stress, aging-related cartilage deterioration, and lifestyle-related risk factors. Increasing demand for minimally invasive therapies that can reduce pain and delay knee replacement procedures is encouraging greater adoption of viscosupplementation treatments among patients and orthopedic specialists.

The segment’s dominance is further supported by the strong clinical focus on knee-specific viscosupplementation therapies and continued product approvals. According to the EUROVISCO Consensus Guidelines published in 2024, the knee is the most common site of osteoarthritis, with a global age-standardized prevalence of 4,307.4 cases per 100,000 people in 2020, and intra-articular hyaluronic acid injections (viscosupplementation) are used in millions of patients worldwide to alleviate pain and reduce disability associated with knee osteoarthritis. This high disease burden and established treatment adoption reinforce the leading position of knee osteoarthritis within the viscosupplementation market.

The viscosupplementation market research report presents the analysis of each segment from 2020 to 2030 considering 2025 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2026 to 2030.

Global Viscosupplementation Market Segmentation:

By Product Type:

• Single Injection
• Three Injection
• Five Injection

By Source:

• Animal-derived Hyaluronic Acid
• Non-animal-derived Hyaluronic Acid

By Application:

• Knee Osteoarthritis
• Hip Osteoarthritis
• Shoulder Osteoarthritis
• Ankle Osteoarthritis
• Others

By End-User:

• Hospitals
• Orthopedic Clinics
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis: The North America Leading the Global Viscosupplementation Market

Geographically, the North America region is expected to dominate the viscosupplementation market, supported by advanced healthcare infrastructure, strong adoption of orthopedic treatments, high availability of specialized healthcare providers, and early acceptance of innovative joint care technologies. The region benefits from a well-established pharmaceutical and medical device ecosystem, favorable access to reimbursement programs, and increasing physician awareness regarding hyaluronic acid-based therapies. The United States remains the major contributor due to its strong healthcare capabilities and growing demand for minimally invasive osteoarthritis management solutions.

The regional leadership is further strengthened by improving reimbursement access and strategic initiatives by key market players to expand patient availability of viscosupplementation treatments. In December 2023, Bioventus Inc. announced a nationwide contract with Aetna Medicare Advantage plans, enabling more than 3 million Aetna Medicare Advantage members to access DUROLANE®, a single-injection hyaluronic acid-based treatment for knee osteoarthritis pain, starting January 2024. This expansion of insurance access highlights the increasing integration of viscosupplementation therapies into mainstream osteoarthritis care pathways and supports continued market growth in North America.

Competitive Analysis:

The viscosupplementation market is highly competitive, with key players focusing on product innovation, regulatory approvals, strategic partnerships, and portfolio expansion to strengthen their market position. Companies are investing in advanced hyaluronic acid formulations, including single-injection and longer-lasting products, to improve patient convenience and treatment effectiveness. The competitive landscape is shaped by the presence of established pharmaceutical and medical device companies with strong orthopedic care portfolios, extensive distribution networks, and increasing focus on minimally invasive osteoarthritis treatment solutions.

Major players in the viscosupplementation market include Anika Therapeutics, Inc., Bioventus Inc., Fidia Farmaceutici S.p.A., Sanofi, Seikagaku Corporation, Zimmer Biomet, and LG Chem. These companies are strengthening their market presence through new product launches, geographic expansion, and strategic collaborations aimed at addressing the growing demand for osteoarthritis management therapies. Increasing competition among manufacturers is also encouraging advancements in hyaluronic acid technology, improved injection techniques, and the development of patient-focused treatment options.

Key Companies:

• Anika Therapeutics, Inc.
• Bioventus Inc.
• Fidia Farmaceutici S.p.A.
• Sanofi
• Seikagaku Corporation
• Zimmer Biomet
• LG Chem
• Ferring Pharmaceuticals
• Lifecore Biomedical
• Chugai Pharmaceutical Co., Ltd.

Global Viscosupplementation Market Outlook

• Growing adoption of minimally invasive osteoarthritis treatments will drive demand for viscosupplementation therapies among patients seeking alternatives to surgery.
• Advancements in hyaluronic acid formulations will improve treatment effectiveness, patient convenience, and acceptance of single-injection products globally.
• Expanding healthcare infrastructure in emerging markets will create new opportunities for viscosupplementation adoption and market penetration.
• Strategic partnerships, product launches, and regulatory approvals will accelerate innovation and strengthen competition among market participants.

Frequently Asked Questions About the Viscosupplementation Market